ログイン
ランキング
お知らせ
ログイン
文献詳細
今月の臨床 最新！ 婦人科がん薬物療法─化学療法薬から分子標的薬・免疫療法薬まで
子宮体がん
文献概要
●まずは初回治療時に再発をさせないための最善の手術療法と有効な補助化学療法を行う．
●再発時の治療法は集学的治療である（手術療法＋化学療法＋放射線治療）．
●子宮体がん治療の展望（新規抗がん薬，ホルモン薬，分子標的治療薬および免疫療法）．
●再発時の治療法は集学的治療である（手術療法＋化学療法＋放射線治療）．
●子宮体がん治療の展望（新規抗がん薬，ホルモン薬，分子標的治療薬および免疫療法）．
参考文献
1）Bokhman JV : Two pathogenetic Types of endometrial carcinoma. Gynecol Oncol 15 : 10─17, 1983
2）International Agency for Research on Cancer : Tumours of the uterine corpus WHO2014, in WHO classification of tumours of female reproductive organs, pp130─131, Lyon, 2013
3）Pennington KP, et al : BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 119 : 332─338, 2013
4）Zorn KK, et al : Gene expression profiles of serous, endometrioid, and clear cell subTypes of ovarian and endometrial cancer. Clin Cancer Res 11 : 6422─6430, 2005
5）Cancer Genome Atlas Research Network : Integrated genomic characterization of endometrial carcinoma. Nature 497 : 67─73, 2013
6）Mahdi H, et al : Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma. J Surg Oncol 112 : 188─194, 2015
7）Santin AD, et al : Regression of chemotherapy-resistant polymerase ε（POLE） ultra-mutated and msh6 hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res 22 : 5682─5687, 2016
8）日本婦人科腫瘍学会作成委員会 : 子宮体がん治療ガイドライン．pp94─143，金原出版，2013
9）FIGO : Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Oncol 105 : 103─104, 2009
10）McMeekin DS, et al : The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials : a Gynecologic Oncology Group study. Gynecol Oncol 106 : 16─22, 2007
11）Price FV, et al : Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma（UPSC）. Gynecol Oncol 51 : 383─389, 1993
12）Levenback C, et al : Uterine papillary serous carcinoma（UPSC） treated with cisplatin, doxorubicin, and cyclophosphamide（PAC）. Gynecol Oncol 46 : 317─321, 1992
13）Ramondetta L, et al : Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol 82 : 156─161, 2001
14）Koshiyama M, et al : Immunohistochemical expression of topoisomerase IIalpha（Topo IIalpha） and multidrug resistance-associated protein（MRP）, plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Anticancer Res 21 : 2925─2932, 2001
15）Boyraz G, et al : Adjuvant treatment, and prognosis in noninvasive uterine papillary serous carcinoma of the endometrium : a retrospective multicenter study. Int J Gynecol Cancer 27 : 102─108, 2017
16）Han KH, et al : Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB. Medicine（Baltimore）. 96 : e6976. 2017
17）Susumu N, et al : Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer : a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108 : 226─233, 2008
18）Todo Y, et al : Survival effect of para-aortic lymphadenectomy in endometrial cancer（SEPAL study） : a retrospective cohort analysis. Lancet 375 : 1165─1172, 2010
19）Todo Y, et al : Tumor volume successively reflects the state of disease progression in endometrial cancer. Gynecol Oncol 129 : 472─477, 2013
20）McGunigal M, et al : Survival differences among uterine papillary serous, clear cell and grade 3 endometrioid adenocarcinoma endometrial cancers : a National Cancer Database analysis. Int J Gynecol Cancer 27 : 85─92, 2017
21）Black C, et al : Uterine papillary serous carcinoma : a single-institution review of 62 cases. Int J Gynecol Cancer 26 : 133─140, 2016
22）Kim HJ, et al : A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system. J Gynecol Oncol 24 : 120─127, 2013
23）Greggi S, et al : Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas : a comparative study. Int J Gynecol Cancer 21 : 661─667, 2011
24）Hamilton CA, et al : Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94 : 642─646, 2006
25）Creasman WT, et al : Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 95 : 593─596, 2004
26）Alagkiozidis I, et al : Survival impact of cytoreduction to microscopic disease for advanced stage cancer of the uterine corpus : a retrospective cohort study. Int J Surg 14 : 61─66, 2015
27）Shimada M, et al : Phase I trial of paclitaxel, doxorubicin, and carboplatin（TAC） for the treatment of endometrial cancer. Int J Gynecol Cancer 17 : 210─214, 2007
28）Ito K, et al : A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer : a Kansai Clinical Oncology Group study（KCOG0015 trial）. Gynecol Oncol 120 : 193─197, 2011
29）Egawa T, et al : Chemotherapy for endometrial carcinoma（GOGO-EM1 study） : TEC（paclitaxel, epirubicin, and carboplatin）is an effective remission-induction and adjuvant therapy. Cancer Chemother Pharmacol 68 : 1603─1610, 2011
30）Shoji T, et al : Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass. Int J Clin Oncol 21 : 1120─1127, 2016
31）Ball HG, et al : A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium : a Gynecologic Oncology Group study. Gynecol Oncol 62 : 278─281, 1996
32）Lissoni A, et al : Phase II study of paclitaxel as salvage treatment in advanced endoemtrial cancer. Ann Oncol 7 : 861─863, 1996
33）Thigpen JT, et al : Phase III trial of doxorubicin with or without cisplatin : a Gynecologic Oncology Group study. J Clin Oncol 22 : 3902─3908, 2004
34）Fleming GF, et al : Randomized phase III study of cispaltin plus doxorubicin with or without paclitadel and filgrastim in endometrial cancer : a Gynecologic Oncology Group study. J Clin Oncol 22 : 2159─2166, 2004
35）Homesley HD, et al : A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel : A Gynecologic Oncology Group study. Gynecol Oncol 112 : 543─552, 2009
36）Reyes HD, et al : High stathmin expression is a marker for poor clinical outcome in endometrial cancer : An NRG oncology group/gynecologic oncology group study. Gynecol Oncol, 2017［Epub ahead of print］
37）Mistry SJ, et al : Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure. Mol Cancer Res 5 : 773─782, 2007
38）Rose PG, et al : Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma. Int J Gynecol Cancer 27 : 452─458, 2017
39）Viswanathan AN, et al : NRG Oncology/RTOG 0921 : A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer 121 : 2156─2163, 2015
40）Kokka F, et al : Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev（12） : CD CD007926, 2010
41）Fleming GF, et al : Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma : a Gynecologic Oncology Group study. Gynecol Oncol 116 : 15─20, 2010
42）Howitt BE, et al : Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 1 : 1319─1323, 2015
43）Ott PA, et al : Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer : results from the KEYNOTE-028 Study. J Clin Oncol, 2017［Epub ahead of print］
44）Nagao S, et al : Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer : the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol 131 : 567─573, 2013
45）Lin JF, et al : Survival advantage associated with multimodal therapy in women with node-positive（stage-IIIC）uterine papillary serous carcinoma : a National Cancer Database study. BJOG 123 : 1846─1852, 2016
46）Xiong S, et al : Activin B induces human endometrial cancer cell adhesion, migration and invasion by up-regulating integrin β3 via SMAD2/3 signaling. Oncotarget 6 : 31659─31673, 2015
47）Lopez S, et al : Dual HER2/PIK3CA targeting overcomes single-agent acquired resistance in HER2-amplified uterine serous carcinoma cell lines in vitro and In vivo. Mol Cancer Ther 14 : 2519─2526, 2015
48）McMeekin DS, et al : A phase I study of IV doxorubicin plus intraperitoneal（IP） paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure（GOG 9920） : an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 138 : 36─40, 2015
49）Damast S, et al : High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. J Contemp Brachytherapy 7 : 35─40, 2015
50）Rauh-Hain JA, et al : Trends in Treatment of Uterine Serous Cancer in the Medicare Population. Int J Gynecol Cancer 25 : 1023─1030, 2015
掲載誌情報
